December 21, 2015: Akrivis Technologies announced today that it was awarded last week a Universal Partnership (UP) Grant from the Massachusetts Life Sciences Center (MLSC), which supports international R&D partnership projects for Massachusetts companies. Akrivis will collaborate with the CEA-Leti, one of the leading French National Research Institutes based in Grenoble, France, to develop ultrasensitive tests for the early detection of cardiac markers of Acute Myocardial Infarction (AMI) and Acute Coronary Syndrome (ACS) on a transportable/portable Point-Of-Care (POC) platform. More info...
November 3, 2015: Akrivis Technologies announced today that it was awarded in September 2015 its second Phase I Small Business Innovation Research (SBIR) Contract by the National Cancer Institute (NCI). Akrivis will collaborate with Washington University School of Medicine in St. Louis (MO) to develop its proprietary ADAPT™ technology platform for a pre-targeted radiotherapy aimed at Acute Myeloid Leukemia (AML). More info...
May 19, 2015: Akrivis Technologies released today its new and improved Z-TECT™ High Sensitivity ELISA Secondary Streptavidin "Anti-Biotin" MonsterHRP™ Kits & Reagents, the most sensitive on the market! To learn more, please upload a flier here.
September 29, 2014: Akrivis Technologies announced today that it was awarded on September 12, 2014, a Phase I SBIR Contract by the NIH/NCI. Akrivis will collaborate with Dana-Farber Cancer Institute and GLG Pharma to develop its proprietary ADAPT™ technology platform for the pre-targeted delivery of high payloads of a small molecule STAT3 inhibitor specifically to cancer stem cells. To learn more, please upload the file here.
June 19, 2014: Akrivis Technologies and CEA-Leti announced their collaboration to develop an extremely adaptable, efficient and highly targeted drug delivery platform for chemotherapy and other treatments that require a high concentration of powerful drugs to be delivered precisely to targeted cells. To learn more, please click here or upload the file here.
September 18, 2012: Akrivis Technologies announced that it has reached a Strategic Alliance and Distribution Agreement with United States Biological Corporation, a world leader in the manufacture and distribution of antibodies and biochemicals used in research laboratories and production facilities. To learn more, please click here.
May 13, 2010: Dr. Joel Berniac (left), Akrivis’ CEO, receives the Young Entrepreneurs Initiative Business Award from Mr. Pierre Vimont, French Ambassador to the United States at the 9th Annual Business Award Dinner organized by the French-American Chamber of Commerce, New England Chapter (FACCNE).
February 23, 2010: Dr. Ban-An Khaw (left), Akrivis’ CSO, and Dr. Joel Berniac(right), Akrivis’ CEO, with Massachusetts Governor Deval Patrick at a "Mass: Start Here" launch event hosted by the Cambridge Innovation Center in Kendall Square, Cambridge.
January 2010: Akrivis Technologies was voted 2010 YEi Laureate (Young Entrepreneurs initiative) by the Office for Science and Technology of the French Embassy in the United States which specializes in putting entrepreneurs in touch with the key resources and partners they need to set up a technology venture in France.
October 2009: Akrivis Technologies was selected among several finalists for the 2009 French-American Innovation Day (FAID) competition on “Theranostics and Biology: Know–How, Challenges, Applications and Breakthroughs”. Final selection will occur on December 4th 2009 in Cambridge, MA (visit www.france-science.org/faid2009).